Background
==========

Graves' disease (GD) is a complex autoimmune thyroid disease, which is caused by excessive production of thyroid hormone and characterized by an enlarged thyroid gland, protrusion of the eyeballs, a rapid heartbeat and nervous excitability \[[@B1]\]. It is reported that GD occurs in about 1.2% in Western population and 0.25--1.09% in Chinese population \[[@B2]\]. It is widely accepted that GD is caused by complex interactions between many genetic factors and environmental factors. Numerous studies have been published focusing on the topic of genetic factors of GD risk in the Chinese population. Many genes involved in the inception and evolution of GD have been identified as GD candidate genes, such as *ADRB2*\[[@B3]\], *TSHR*\[[@B4]\], *CTLA-4*\[[@B5]\] and *IL-13* gene \[[@B6]\]. And among them, the *CTLA-4* gene is one of the most extensively studied.

Cytotoxic T lymphocyte-associated molecule-4 (*CTLA-4*) is a T cell surface molecule \[[@B7]\]. It is a negative regulator of T cell activation and plays an important role in the pathogenesis of GD. The *CTLA-4* gene is localized on chromosome 2q33. Many polymorphisms have been identified in the *CTLA-4* gene. It is reported that the polymorphisms in *CTLA-4* gene might influence the expression of the protein, and might play important roles in the pathogenesis of GD \[[@B8]\]. Up to now, many studies have been performed to investigate the associations between the polymorphisms in the *CTLA-4* gene and the risk of GD. Among them, the +49A/G, -318C/T and CT60 polymorphisms were the most widely studied. To this day, the associations between polymorphisms of the *CTLA-4* gene and the risk of GD have been widely investigated in the Chinese population. However, the results were inconsistent, and the associations were not yet formally evaluated. In order to derive a more precise conclusion, we performed a meta-analysis to assess the associations between the polymorphisms in the *CTLA-4* gene and the risk of GD in the Chinese population. To our knowledge, this is the first comprehensive genetic meta-analysis performed in the Chinese population for Graves' disease.

Methods
=======

Study identification and selection
----------------------------------

A literature search in Pubmed database, Medline (Ovid) database, CNKI database and Wanfang database was carried out to identify studies investigating the association between the Graves' disease risk and the *CTLA-4* polymorphisms on Aug 11th, 2012. The search terms were as follows: *Graves' disease* or *GD* in combination with *polymorphism* or *variant* or *mutation* and in combination with *CTLA-4* or Cytotoxic T lymphocyte-associated molecule-4*.* All languages were included. The inclusion criteria were: (a) studies evaluating the association between the (+49A/G, -318C/T and CT60) polymorphisms in the *CTLA-4* gene and Graves' disease risk in the Chinese population, (b) the design should be a case--control design, (c) sufficient data (genotype distributions of cases and controls) available to calculate an odds ratio (OR) with its 95%CI (confidence interval), (d) genotype distributions in control group should be consistent with Hardy-Weinberg equilibrium (HWE). Studies were excluded if one of the following existed: (a) the studied populations were based on family or sibling pairs, (b) genotype frequencies or numbers were not presented in the original studies, (c) reviews and abstracts. If more than one study was published by the same authors using the same case series or overlapping case series, studies with the largest size of samples were included.

Data extraction
---------------

Two investigators independently extracted the data and reached a consensus on all items. The following items were extracted from each study if available: first author's name, publication year, province of origin, age of cases, genotype number in cases and controls and genotyping method.

Statistical analysis
--------------------

The strength of associations between the polymorphisms in the *CTLA-4* gene and Graves' disease risk was assessed by odds ratios (OR) with the corresponding 95% confidence intervals (CI). The genetic models evaluated for the pooled OR of the polymorphisms were dominant models (GG+GA vs. AA for the +49A/G, TT+TC vs. CC for the -318C/T, and AA+AG vs. GG for the CT60). OR was analyzed by a fixed-effects model (the Mantel-Haenszel method) or a random-effects model (the DerSimonian and Laird method) according to the heterogeneity. Heterogeneity was assessed by a *X*^*2*^ based *Q* statistic and was considered statistically significant at *p*-value \<0.10. When the *P* value was more than 0.10, the pooled OR was calculated by the fixed-effects model, otherwise, a random-effects model was used. The significance of the pooled OR was determined by the *Z*-test and *p*-value less than 0.05 was considered as statistically significant. Sensitivity analysis was conducted by sequential excluding a single study each time in an attempt to identify the potential influence of the individual data set to the pooled ORs. In addition, the possible publication bias was investigated with the Begg's funnel plot. Funnel plot asymmetry was assessed by Egger's linear regression test \[[@B9]\]. For each polymorphism, other genetic models were also used to assess the association with the risk of Graves' disease (for the +49A/G polymorphism: GG vs. AA+GA, GG vs. AA, GA vs. AA, G vs. A; for the -318C/T polymorphism: TT vs. CC+TC, TT vs. CC, TC vs. CC, T vs. C; for the CT60 polymorphism: AA vs. AG+GG, AA vs. GG, AG vs. GG, A vs. G). HWE was tested by Person's *X*^*2*^ test. Statistical analysis was performed using Revman4.2 software and Stata10.0 software.

Results
=======

Studies selection and characteristics
-------------------------------------

The selection process of studies was as follows. Briefly, a total of 429 results were identified after an initial search from the Pubmed, Medline (Ovid), CNKI and Wanfang databases. After reading the titles and abstracts, 302 results were excluded for being irrelevant to *CTLA-4* polymorphisms and Graves' disease risk, abstracts, reviews or duplications of search results. After reading full-texts of the remaining 127 studies, 68 studies were excluded for not relevant to the GD risk in the Chinese population, and 9 studies were excluded for not relevant to the investigated polymorphisms (+49A/G, -318C/T and CT60). Thus, 50 studies were left for data extraction. And then, a total of 54 case--control studies were extracted for these three polymorphisms. Among 54 case--control studies, genotype numbers for control group in 7 studies were not consistent with HWE, data in 19 studies were overlapped. So these 27 case--control studies were excluded. Finally, a total of 28 case--control studies in 21 publications were identified for meta-analysis \[[@B2],[@B10]-[@B27]\]. Summary of the properties of the studies are listed in Table  [1](#T1){ref-type="table"}. Overall, there were 17 case-controls studies for the +49A/G polymorphism \[[@B2],[@B5],[@B11]-[@B13],[@B15],[@B17]-[@B25],[@B27],[@B28]\], 7 case--control studies for the -318C/T polymorphism \[[@B2],[@B10]-[@B12],[@B14],[@B26],[@B28]\] and 4 case--control studies for the CT60 polymorphism \[[@B2],[@B10],[@B16],[@B18]\]. The genotype distributions for these polymorphisms are listed in Table  [2](#T2){ref-type="table"}.

###### 

Properties of the 21 case--control studies included in meta-analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
        **Author**         **Publication year**              **Province**               **Case age(year)**   **Case number**   **Control number**   **Genotyping method**     **Polymorphisms**
  ----------------------- ---------------------- ------------------------------------- -------------------- ----------------- -------------------- ----------------------- -----------------------
   Chong, K K \[[@B10]\]           2008                        Hong Kong                       \<16                177                151                 PCR-RFLP              −318C/T, CT60

    Du, Y T \[[@B11]\]             2005                         Tianjin                         \-                 96                  60                 PCR-PFLP             +49A/G, -318C/T

    Guo, Z Q \[[@B12]\]            2010                        Shandong                    44.17 ± 1.54            102                100                 PCR-PFLP             +49A/G, -318C/T

    Han, S Z \[[@B2]\]             2006                        Chongqing                        \-                 263                196                 PCR-PFLP          +49A/G, -318C/T, CT60

   Jiang, B R \[[@B13]\]           2005                        Shandong                    43.8 ± 13.5             98                  95                 PCR-PFLP                 +49A/G

   Kang, Y Z \[[@B14]\]            2010                         Ningxia                    43.7 ± 11.5             61                  60                 PCR-PFLP                 −318C/T

   Shen, F X \[[@B15]\]            2005                        Zhejiang                    36.0 ± 12.3             107                 57                 PCR-PFLP                 +49A/G

   Tsai, S T \[[@B16]\]            2008                         Taiwan                      10.2 ± 3.3             189                620                 PCR-RFLP                  CT60

    Wang, L \[[@B17]\]             2001                        Shandong                      40 ± 13               87                  84                 PCR-PFLP                 +49A/G

   Wang, P W \[[@B18]\]            2007                         Taiwan                       39 ± 13               208                192                 PCR-RFLP              +49A/G, CT60

   Wang, Q H \[[@B19]\]            2003                        Zhejiang                     45.7 ± 9.5             64                  28                 PCR-PFLP                 +49A/G

   Wang, S Q \[[@B20]\]            2010                        Shandong                    41.5 ± 28.5             90                  90                 PCR-PFLP                 +49A/G

   Weng, Y C \[[@B21]\]            2005                         Taiwan                     34.0 ± 11.8             107                101                 PCR-PFLP                 +49A/G

    Yang, J \[[@B22]\]             2012                          Xi'an                    34.14 ± 12.23            303                215                 PCR-PFLP                 +49A/G

     Yao, B \[[@B23]\]             2005                        Guangdong                   36.6 ± 12.8             120                123                PCR-PFLP,\                +49A/G
                                                                                                                                                          PCR-SSLP         

    Yu, Q L \[[@B24]\]             2006                        Guangdong                     45 ± 11               100                100                 PCR-PFLP                 +49A/G

    Yu, Z Y \[[@B25]\]             2008                          Xi'an                     36.7 ± 13.28            125                126                 PCR-RFLP                 +49A/G

    Zhang, H \[[@B26]\]            2010                        Shandong                         \-                 211                 85                 PCR-PFLP                 −318C/T

   Zhang, J L \[[@B27]\]           2008                        Shandong                    37.8 ± 13.3             186                100                 PCR-PFLP                 +49A/G

    Zhang, Q \[[@B28]\]            2006                        Zhejiang                         \-                 89                  60                 PCR-RFLP             +49A/G, -318C/T

    Zhao, S X \[[@B5]\]            2010           Shandong, Suzhou, Guangdong, Fujian           \-                2640                2204               Mass-Array™               +49A/G
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

**Distribution of*CTLA-4*genotype among patients with Graves' disease and controls included in the meta-analysis**

     **Polymorphism**           **Author**        **Case**   **Control**   **Case**   **Control**   **HWE**                                   
  ----------------------- ---------------------- ---------- ------------- ---------- ------------- --------- ----- ------ ------ ------ ----- -----
    +49A/G polymorphism                              AA          AG           GG          AA          AG      GG     A      G      A      G      
    Du, Y T \[[@B11]\]              1                27          68           7           26          27      29    163     40     80    Yes  
    Guo, Z Q \[[@B12]\]             24               52          26           41          47          12      100   104    129     71    Yes  
    Han, S Z \[[@B2]\]              33               95          135          32          89          75      161   365    153    239    Yes  
   Jiang, B R \[[@B13]\]            10               44          44           33          46          16      64    132    112     78    Yes  
   Shen, F X \[[@B15]\]             5                34          68           4           30          23      44    170     38     76    Yes  
    Wang, L \[[@B17]\]              3                47          37           32          42          10      53    121    106     62    Yes  
   Wang, P W \[[@B18]\]             15               69          124          18          77          97      99    317    113    271    Yes  
   Wang, Q H \[[@B19]\]             21               24          19           12          15           1      66     62     39     17    Yes  
   Weng, Y C \[[@B21]\]             8                53          46           15          58          28      69    145     88    114    Yes  
   Wang, S Q \[[@B20]\]             5                47          38           24          52          14      57    123    100     80    Yes  
    Yang, J \[[@B22]\]              12              139          152          29          97          89      163   443    155    275    Yes  
     Yao, B \[[@B23]\]              9                53          58           11          57          55      71    169     79    167    Yes  
    Yu, Q L \[[@B24]\]              13               36          51           28          46          26      62    138    102     98    Yes  
    Yu, Z Y \[[@B25]\]              13               45          67           20          60          46      71    179    100    152    Yes  
   Zhang, J L \[[@B27]\]            16              100          70           32          43          25      132   240    107     93    Yes  
    Zhang, Q \[[@B28]\]             2                29          58           7           26          27      33    145     40     80    Yes  
    Zhao, S X \[[@B5]\]            104              730         1030         156          823         945     938   2790   1135   2713   Yes  
   −318C/T polymorphism                              CC          CT           TT          CC          CT      TT     C      T      C      T      
   Chong, K K \[[@B10]\]           147               28           2          122          29           0      322    32    273     29    Yes  
    Du, Y T \[[@B11]\]              80               13           3           46          12           2      173    19    104     16    Yes  
    Guo, Z Q \[[@B12]\]             84               18           0           76          23           1      186    18    175     25    Yes  
   Kang, Y Z \[[@B14]\]             52               8            1           48          11           1      112    10    107     13    Yes  
    Zhang, H \[[@B26]\]            175               35           1           69          16           0      385    37    154     16    Yes  
    Han, S Z \[[@B2]\]             159               98           2          103          85           2      416    26    291    101    Yes  
    Zhang, Q \[[@B28]\]             65               22           6           46          12           8      152   110    104     16    Yes  
     CT60 polymorphism                               GG          AG           AA          GG          AG      AA     G      A      G      A      
   Chong, K K \[[@B10]\]           125               48           4           88          51          12      298    56    227     75    Yes  
    Han, S Z \[[@B2]\]             184               71           8          123          60          13      439    87    306     86    Yes  
   Tsai, S T \[[@B16]\]            136               48           5          372          216         32      320    58    960    280    Yes  
                           Wang, P W \[[@B18]\]     138          46           5           125         58       9    322     56    308    76    Yes

Quantitative synthesis
----------------------

### The +49A/G polymorphism

A total of 4009 cases and 3651 controls from 17 case--control studies were included for data synthesis. As is shown in Figure  [1](#F1){ref-type="fig"}, we analyzed the heterogeneity of GG+GA vs. AA for all 17 studies and the value of *X*^*2*^ was 47.22 with 16 degrees of freedom and *p*-value \< 0.00001 in a random-effects model. Additionally, I-square value is another index of the test of heterogeneity. In Figure  [1](#F1){ref-type="fig"}, the I-square was 66.1%, suggesting a moderate of heterogeneity. Thus, we chose the random-effects model to synthesize the data. Overall, OR was 2.57 (95%CI = 1.87-3.52) and the test for overall effect *Z* value was 5.83 (*p*-value \< 0.00001). The results suggested that the G allele carriers might have an increased risk of Graves' disease compared with those individuals with the AA homozygote. Statistically similar results were obtained after sequential excluding each case--control study for the GG+GA vs. AA comparative, suggesting the stability of our meta-analysis. Significant publication bias was detected in the funnel plot (figure not shown), and in the Egger's test, the result was: t = 2.82, *p*-value = 0.013, which also indicated considerable publication bias. Summary of the results of other genetic comparisons are listed in Table  [3](#T3){ref-type="table"}.

![**Meta-analysis with a random-effects model for the association between GD risk and the*CTLA-4*+49A/G polymorphism (GG+GA vs. AA).**](1471-2350-14-46-1){#F1}

###### 

Summary of different comparative results

   **Polymorphism**   **Genetic model**   **Participants**   **OR (95%CI)**    ***Z***   ***p*-value**   **I**^**2**^**, %**   ***P***~**Het**~   **Effect model**
  ------------------ ------------------- ------------------ ----------------- --------- --------------- --------------------- ------------------ ------------------
        +49A/G          GG+GA vs. AA            7660         2.57(1.87,3.52)    5.83      \< 0.00001            66.1              \< 0.0001            Random
                        GG vs. GA+AA            7660         2.11(1.70,2.63)    6.69      \< 0.00001            70.3              \< 0.00001           Random
                          GG vs. AA             4402         3.87(2.59,5.80)    6.57      \< 0.00001            74.3              \< 0.00001           Random
                          GA vs. AA             4053         1.96(1.44,2.67)    4.25      \< 0.00001            60.8                0.0006             Random
                           G vs. A             15320         1.88(1.58,2.23)    7.18      \< 0.00001            76.8              \< 0.00001           Random
       −318C/T          TT+TC vs. CC            1701         0.78(0.62,0.97)    2.18         0.03                 0                  0.86              Fixed
                        TT vs. TC+CC            1701         0.76(0.37,1.53)    0.78         0.44                 0                  0.92              Fixed
                          TT vs. CC             1291         0.70(0.35,1.43)    0.97         0.33                 0                  0.90              Fixed
                          TC vs. CC             1672         0.78(0.62,0.98)    2.11         0.03                 0                  0.86              Fixed
                           T vs. C              3402         0.80(0.66,0.98)    2.12         0.03                 0                  0.88              Fixed
       CT60 G/A        AA + AG vs. GG           1977         0.64(0.52,0.78)    4.34       \< 0.0001              0                  0.82              Fixed
                       AA vs. AG + GG           1977         0.43(0.26,0.72)    3.22         0.001                0                  0.82              Fixed
                          AA vs. GG             1379         0.39(0.23,0.65)    3.62        0.0003                0                  0.81              Fixed
                          AG vs. GG             1889         0.69(0.55,0.85)    3.52        0.0004                0                  0.82              Fixed
                           A vs. G              3954         0.65(0.54,0.77)     4.9      \< 0.00001              0                  0.81              Fixed

### The -318C/T polymorphism

A total of 999 cases and 702 controls from 7 case--control studies were included for data synthesis. As is shown in Figure  [2](#F2){ref-type="fig"}, we analyzed the heterogeneity of TT+TC vs. CC for all 7 studies and the value of *X*^*2*^ was 2.56 with 6 degrees of freedom and *p*-value = −0.86 in a fixed-effects model. Additionally, I-square value is another index of the test of heterogeneity. In Figure  [2](#F2){ref-type="fig"}, the I-square was 0%, suggesting an absent of heterogeneity. Thus, we chose the fixed-effects model to synthesize the data. Overall, OR was 0.78 (95%CI = 0.62-0.97) and the test for overall effect *Z* value was 2.18 (*p*-value = 0.03). The results suggested that the T allele carriers might have a decreased risk of Graves' disease compared with those individuals with the CC homozygote. Statistically similar results were obtained after sequential excluding each case--control study for the TT+TC vs. CC comparative, suggesting the stability of our meta-analysis. No publication bias was detected with either the funnel plot (figure not shown) or Egger's test (t = 0.09, *p*-value = 0.929). Summary of the results of other genetic comparisons are listed in Table  [3](#T3){ref-type="table"}.

![**Meta-analysis with a random-effects model for the association between GD risk and the*CTLA-4*-318C/T polymorphism (TT+TC vs. CC).**](1471-2350-14-46-2){#F2}

### The CT60 polymorphism

A total of 818 cases and 1159 controls from 4 case--control studies were included for data synthesis. As is shown in Figure  [3](#F3){ref-type="fig"}, we analyzed the heterogeneity of AA+AG vs. GG for all 4 studies and the value of *X*^*2*^ was 0.91 with 3 degrees of freedom and *p*-value = 0.82 in a fixed-effects model. Additionally, I-square value is another index of the test of heterogeneity. In Figure  [3](#F3){ref-type="fig"}, the I-square was 0%, suggesting an absent of heterogeneity. Thus, we chose the fixed-effects model to synthesize the data. Overall, OR was 0.64 (95%CI = 0.52-0.78) and the test for overall effect *Z* value was 4.34 (*p*-value = 0.001). The results suggested that the A allele carriers might have a decreased risk of Graves' disease compared with those individuals with the GG homozygote. Statistically similar results were obtained after sequential excluding each case--control study for the AA+AG vs. GG comparative, suggesting the stability of our meta-analysis. No publication bias was detected with either the funnel plot (figure not shown) or Egger's test (t = 0.19, *p*-value = 0.864). Summary of the results of other genetic comparisons are listed in Table  [3](#T3){ref-type="table"}.

![**Meta-analysis with a random-effects model for the association between GD risk and the*CTLA-4*CT60 polymorphism (AA+AG vs. GG).**](1471-2350-14-46-3){#F3}

Discussion
==========

Graves\' disease (GD) is a thyroid-specific autoimmune disease affecting 0.25--1.09% of the Chinese population \[[@B2]\]. To this day, the mechanisms of GD have been widely studied from the environmental factors to the genetic factors \[[@B29]\]. However, the results are inconsistent and the exact mechanisms are still unrevealed. Among genetic risk factors, the *cytotoxic T lymphocyte associated-4* (*CTLA-4*) gene is one of the widely investigated. *CTLA-4* gene, which encodes a vital negative regulatory molecule of the immune system \[[@B30]\], has been demonstrated as candidate gene of GD \[[@B31],[@B32]\]. To date, three polymorphisms (+49A/G, -318C/T and CT60) have been suggested as GD risk factors in the Chinese population. However, the results were inconsistent. Therefore, we performed a comprehensive meta-analysis to assess the association and to get more conclusive results.

This meta-analysis, including a total of 28 case--control studies in 21 publications, investigated three most widely studied polymorphisms in the *CTLA-4* gene. We found that the +49A/G polymorphism was associated with an increased risk of GD in the Chinese population, and the G allele carriers might have a higher risk of disease than the AA homozygote carriers. The results suggested a significant association between this polymorphism in the Chinese population, which is consistent with some other populations, such as the UK population \[[@B33]\] and the Iranian population \[[@B34]\]. Our results indicated that the increase in the risk is more evident in the Chinese population than in other populations, suggesting possible roles of ethnic differences in genetic backgrounds and the environment. In addition, the +49A/G polymorphism is located in exon 1, and results in a threonine-to-alanine conversion at codon 17 in the peptide leader sequence of the CTLA-4 protein. It reported that this polymorphism was associated with lower mRNA levels of the soluble alternative splice form of CTLA-4 \[[@B35]\]. Thus, our results could be partly explained that the variant carriers might have lower mRNA levels of the protein of the CTLA-4, and then have increased risk of the disease. In future, more studies should be performed in the Chinese population to validate these results.

A total of 999 cases and 702 controls from 7 case--control studies were included for the -318C/T polymorphism. The results suggested that the T allele carriers might be associated with a decreased risk of GD compared with CC homozygote carriers. As for the CT60 polymorphism, 818 cases and 1159 controls from 4 case--control studies were included, and the results also indicated a decrease in the risk of GD. Considering the included case--control studies for both polymorphisms were relatively small, larger number of relevant studies are needed in future to validate these results.

Hitherto, many studies have already been published focusing on the genetic risk factors of the GD among the Chinese population. For instance, Chu reported that a non-synonymous single-nucleotide polymorphism rs40401 (P27S) of the *interleukin 3* (*IL3*) gene was associated with increased risk of GD \[[@B36]\]; Guo found the rs568408 polymorphism in the *interleukin-12* (*IL-12*) gene was also associated with increased risk of GD \[[@B37]\]. In addition, polymorphisms in the *ADRB2* gene \[[@B3]\], *interleukin-10* (*IL-10*) gene \[[@B38]\], *TNF-α* gene \[[@B39]\] were also found to be associated with GD in Chinese population. These genes were all suggested as the candidate genes for GD in Chinese population. In future, the associations between these polymorphisms and the GD risk in Chinese population are needed to be validated by more case--control studies.

In the present meta-analysis, sensitivity analysis was performed and stability of the results was guaranteed. Publication bias was assessed by Begg's funnel plot and Egger's test \[[@B40]\]. No significant publication bias was found for the -318C/T and the CT60 polymorphism analysis, suggesting the results of these two polymorphisms were more reliable. However, we found significant publication bias for the +49A/G polymorphism. The reason might be that some reports were not published, especially for those with negative results. The results might affect the strength of the association, thus, large scale case--control studies are needed to assess the association between the +49A/G polymorphism and GD risk.

We have to mention the heterogeneity. We found significant heterogeneity for the +49A/G polymorphism. Since all participants were Chinese, the genetic background might not be taken as a factor for the heterogeneity for +49A/G polymorphism. However, some other factors, such as gender, age and location might affect the heterogeneity. In addition, we found no heterogeneity for the -318C/T and the CT60 polymorphisms, which suggested that the association for these two polymorphisms are more reliable than the +49A/G polymorphism.

It is reported that GD occurs more frequently but less severe in women than in men. In China, the different condition of disease in men and women might be similar to the situation of the world. In our study, the data was not analyzed by gender because of the lack of original information for these populations. In future, such subgroup studies are also needed to be carried out. Moreover, the cases and controls in this meta-analysis were mostly based on Han nationality, but not in the minorities. In order to get comprehensive results of the Chinese population, studies based on the minorities are also needed.

There are several limitations in this meta-analysis. First, the quantity of enrolled published studies was not very ideal, especially for the -318C/T and CT60 polymorphism. This might cause some potential publication bias, although the results of the above mentioned bias tests was not significant for these two polymorphisms. Second, data were not stratified into subgroups according to some other factors such as age, gender, location and ethnicity (Han or others), due to the lack of information in the original studies. Third, the interactions between genetic factors and environmental factors were not discussed for these three polymorphisms. Fourth, the current meta-analysis only investigated the three most widely studied polymorphisms, and some other polymorphisms with fewer reports were not included. And in future, if there were more case--control studies, new meta-analysis should be conducted. Despite of these limitations, we have minimized the bias through the whole process based on means in study identification, data selection and statistical analysis as well as in the control of publication bias and sensitivity, and got a more reliable result.

Conclusions
===========

To our knowledge, this is the first comprehensive genetic meta-analysis performed in Chinese population for Graves' disease and *CTLA-4* gene. We found that three polymorphisms (+49A/G, -318C/T and CT60) in the *CTLA-4* gene were associated with the risk of GD. Our results supported the classic view that GD is associated with heredity and revealed that genes in the pathogenesis are important for GD. These results may have implications for further medicine researches about GD for the Chinese population. In future, more large-scale case--control studies are needed to validate our results.

Competing interests
===================

The authors declare that they have no competing interests.

Authors' contributions
======================

LD designed the research. JH and JQY searched the publications, extracted the data and wrote the article. YGZ checked all data. JCH and ZPX was responsible for data synthesis and helped designed the study's analytic strategy. YGZ and LD edited the manuscript. YXM, TYX and HCW revised the manuscript. All authors read and approved the final manuscript.

Pre-publication history
=======================

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2350/14/46/prepub>

Acknowledgements
================

This study was supported by grants 81101939 from National Natural Science Foundation of China.
